#3-80E. Navigating Gout Management and Treat-to-Target Strategies (NEJM, 2022)

Gout is a frequently encountered condition in daily practice, but managing it in patients with multiple comorbidities can often pose a clinical dilemma. This review comprehensively outlines the pathophysiology of gout as a chronic disease of monosodium urate deposition and emphasizes the importance of a step-up approach to urate-lowering therapy, targeting a serum urate level of less than 6.0 mg/dL. A pivotal clinical takeaway from this article is that a treat-to-target strategy remains highly effective and safe even in patients with concurrent moderate-to-severe chronic kidney disease. While this finding strongly supports aggressive urate control, clinicians must critically navigate the landscape of conflicting guidelines, particularly noting the divergence between rheumatology subspecialty societies that advocate for a treat-to-target approach and the American College of Physicians, which endorses a treat-to-avoid-symptoms strategy. For practicing physicians, understanding these nuances is crucial, as it directly guides optimal pharmacological choices tailored to patients who frequently present with overlapping cardiovascular and renal comorbidities.

Citation: Mikuls TR. Gout. The New England Journal of Medicine. 2022. DOI: 10.1056/NEJMcp2203385

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.